3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Breast Neoplasms
8
Salivary Gland Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Pathologic Complete Response
1
Hemangiosarcoma
1
Heart Failure
1
HER2-positive Metastatic Breast Cancer
1
HER2-positive Breast Cancer
1
HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Brain Neoplasms
1
Adenocarcinoma Of Esophagus
1
Interventions
pembrolizumab
25
Paclitaxel
20
Carboplatin
17
Bevacizumab
12
Specimen Handling
10
Letrozole
10
abemaciclib
7
dostarlimab
6
Taxes
6
Blood Specimen Collection
6
Medroxyprogesterone Acetate
5
Magnetic Resonance Spectroscopy
5
Fulvestrant
5
Drug Therapy
5
Doxorubicin
5
Cisplatin
5
Biopsy
5
olaparib
4
lenvatinib
4
atezolizumab
4
Radiotherapy
4
Progestins
4
Observation
4
Nivolumab
4
Megestrol Acetate
4
Immunoglobulin G
4
Gemcitabine
4
trastuzumab deruxtecan
3
palbociclib
3
X-Rays
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Endometrial Neoplasms
×
Ado-Trastuzumab Emtansine
×
Clear all
NCT04486352
2026-04-01
EndoMAP
Alliance Foundation Trials, LLC.
Phase 1/2
Recruiting
148 enrolled